[HTML][HTML] Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
…, Y Qian, P Cui, D Huang, Z Huang, Z Wu… - Frontiers in …, 2021 - frontiersin.org
Background Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have demonstrated
promise in treating a variety of advanced cancers; however, little is known regarding …
promise in treating a variety of advanced cancers; however, little is known regarding …
[HTML][HTML] The PI3K/Akt/GSK-3β/ROS/eIF2B pathway promotes breast cancer growth and metastasis via suppression of NK cell cytotoxicity and tumor cell susceptibility
F Jin, Z Wu, X Hu, J Zhang, Z Gao, X Han… - Cancer biology & …, 2019 - ncbi.nlm.nih.gov
Objective To examine the effect of pSer9-GSK-3β on breast cancer and to determine
whether the underlying metabolic and immunological mechanism is associated with ROS/eIF2B …
whether the underlying metabolic and immunological mechanism is associated with ROS/eIF2B …
The synergistic effect of PARP inhibitors and immune checkpoint inhibitors
Z Wu, P Cui, H Tao, S Zhang, J Ma… - Clinical Medicine …, 2021 - journals.sagepub.com
Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated great promise for
treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 …
treating cancers with homologous recombination (HR) defects, such as germline BRCA1/2 …
PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism
N Li, J Qin, L Lan, H Zhang, F Liu, Z Wu… - Cancer biology & …, 2015 - Taylor & Francis
PTEN has been studied in several tumor models as a tumor suppressor. In this study, we
explored the role of PTEN in the inhibition state of polarized M2 subtype of macrophage in …
explored the role of PTEN in the inhibition state of polarized M2 subtype of macrophage in …
[HTML][HTML] Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
P Cui, R Li, Z Huang, Z Wu, H Tao, S Zhang, Y Hu - Scientific Reports, 2020 - nature.com
The efficacies of pembrolizumab and nivolumab have never been directly compared in a
real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (…
real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (…
Downregulation of MCT 4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma
Y Long, Z Gao, X Hu, F Xiang, Z Wu, J Zhang… - Cancer …, 2018 - Wiley Online Library
Monocarboxylate transporter‐4 ( MCT 4), a monocarboxylic acid transporter, demonstrates
significantly increased expression in the majority of malignancies. We performed an …
significantly increased expression in the majority of malignancies. We performed an …
[HTML][HTML] Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
…, G Chen, X Li, J Zhang, P Cui, W Du, Z Wu… - Cancer Immunology …, 2019 - Springer
Background Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is
limited and unsatisfactory. Methods Chinese BTC patients receiving a PD-1 inhibitor with …
limited and unsatisfactory. Methods Chinese BTC patients receiving a PD-1 inhibitor with …
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
P Cui, D Huang, Z Wu, H Tao, S Zhang… - … in medical oncology, 2020 - journals.sagepub.com
Background: Cutaneous adverse events (AEs) have been positively associated with immune
checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding …
checkpoint inhibitor (ICI) efficacy in patients with melanoma, but little is known regarding …
Association of the pretreatment lung immune prognostic index with survival outcomes in advanced hepatocellular carcinoma patients treated with PD-1 inhibitors
…, L Wang, P Cui, Z Zhang, D Huang, Z Wu… - Journal of …, 2020 - Taylor & Francis
Purpose At present, there are no validated biomarkers that can predict whether patients with
advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We …
advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We …
Tumor mutation burden as a potential biomarker for PD-1/PD-L1 inhibition in advanced non-small cell lung cancer
…, J Ma, J Wang, Z Liu, P Cui, S Chen, Z Huang, Z Wu… - Targeted Oncology, 2020 - Springer
Background Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed
death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung …
death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment of non-small cell lung …
